Sita D. Bhella

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: June 15, 2026

Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1.

Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 20, 2026

Correction: Added prognostic value of baseline pre-infusion 18F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy.

Correction: Added prognostic value of baseline pre-infusion 18F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy.

Journal: Scientific reports

Published: January 28, 2026

Medication-related osteonecrosis of the jaw: incidence and risk factors in multiple myeloma patients undergoing pre-autologous stem cell transplant dental extractions.

Medication-related osteonecrosis of the jaw: incidence and risk factors in multiple myeloma patients undergoing pre-autologous stem cell transplant dental extractions.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: January 14, 2026

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 06, 2026

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.

Journal: Hematological oncology

Published: November 03, 2025

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal Impairment.

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal Impairment.

Journal: European journal of haematology

Published: October 09, 2025

GVHD Prophylaxis With ATG and PTCy Versus PTCy-Based Regimens in Haploidentical Stem Cell Transplantation: A CTTC Study.

GVHD Prophylaxis With ATG and PTCy Versus PTCy-Based Regimens in Haploidentical Stem Cell Transplantation: A CTTC Study.

Journal: Transplantation and cellular therapy

Published: October 07, 2025

Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study.

Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study.

Journal: Blood

Published: September 30, 2025

Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.

Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.

Journal: Blood cancer discovery

Published: September 30, 2025

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study.

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study.

Journal: Blood

Published: September 30, 2025

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias.

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias.

Journal: Blood advances

Published: August 18, 2025

Showing 1-12 of 49

Last Updated: 09/26/2026